RND is an In-Silico Bioinformatics Company Focusing on Targets and Markers of Peripheral Immune Resistance.
Business Model
Partnering for Co-Development and Commercialization
Research and Development
RND has developed an extensive Bioinformatics database with Human Targets/Markers related to Immune Peripheral Resistance Mechanisms, which Targets/Markers are validated against Clinical Outcomes of Immunotherapy.
Our Product Development Strategy is three-fold: 1. To Develop a Test Predictive of Resistance to Immunotherapy 2. To Develop a Spatial Biology tool with Immune Peripheral Resistance Markers to aid IO Drug Discovery 3. To Develop Therapeutics that can Overcome Resistance to Immunotherapy